Sarepta Hits Early Win With New siRNA Drugs for Rare Muscle Diseases – Beating Rivals on Delivery and Safety

Sarepta just shared first test results for two new medicines aimed at rare muscle diseases FSHD1 and DM1. Early data show the drugs reach high levels in muscle safely, with no serious side effects. Shares jumped.